Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Rated "Hold" by Sell-Side Brokerages

Key Points

• Supernus Pharmaceuticals carries a consensus “Hold” rating from six brokerages, with two sells, one hold, and three buys; the average 12-month price target is $62.40 versus a share price of $42.81.
• Several institutional investors recently initiated positions, led by BlackRock with an approximately $434.9 million stake, alongside new investments from Bank of America, Assenagon Asset Management, Rice Hall James & Associates, and Bank of New York Mellon.
• The company’s latest quarter showed revenue growth of 32.4% year over year to $219.1 million, exceeding estimates, but it reported an adjusted loss of $1.01 per share compared with the expected $0.42 profit.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) have received an average rating of "Hold" from the six brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $62.40.

A number of brokerages have recently commented on SUPN. Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Monday, September 21st. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Finally, Zacks Research lowered Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Monday, October 5th.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently made changes to their positions in SUPN. BlackRock Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $434,871,000. Bank of America Corp DE bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $28,887,000. Assenagon Asset Management S.A. bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $27,428,000. Rice Hall James & Associates LLC bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $22,800,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $17,553,000.

Supernus Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:SUPN opened at $42.81 on Tuesday. Supernus Pharmaceuticals has a 12 month low of $40.51 and a 12 month high of $59.68. The company's fifty day simple moving average is $44.25 and its 200 day simple moving average is $46.66. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -22.30, a PEG ratio of 0.79 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company's revenue was up 32.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.40 earnings per share. Research analysts expect that Supernus Pharmaceuticals will post 1.97 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company's portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.